Citigroup
LPCN icon

Citigroup’s Lipocine LPCN Stock Holding History

Citigroup’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$9 – 6287
2025
Q3 		$9 Buy
+3
New +$9 ﹤0.01% 5949
2022
Q2 		– Sell
-29
Closed -$1K – 6473
2022
Q1 		$1K Buy
+29
New +$607 ﹤0.01% 6189
2018
Q1 		– Sell
-203
Closed -$12K – 7604
2017
Q4 		$12K Hold
203
– – ﹤0.01% 6957
2017
Q3 		$14K Buy
+203
New +$14.7K ﹤0.01% 6583
2017
Q2 		– Sell
-3
Closed -$196 – 7422
2017
Q1 		$0 Sell
3
-978
-100% -$63.4K ﹤0.01% 7268
2016
Q4 		$61K Buy
981
+901
+1,126% +$57K ﹤0.01% 6048
2016
Q3 		$6K Sell
80
-371
-82% -$23K ﹤0.01% 6716
2016
Q2 		$23K Buy
451
+389
+627% +$60.2K ﹤0.01% 6066
2016
Q1 		$10K Sell
62
-19
-23% -$3.24K ﹤0.01% 6798
2015
Q4 		$18K Buy
81
+22
+37% +$4.62K ﹤0.01% 6535
2015
Q3 		$12K Buy
+59
New +$13.7K ﹤0.01% 6332
2015
Q1 		– Sell
-294
Closed -$26K – 7317
2014
Q4 		$26K Buy
+294
New +$24.8K ﹤0.01% 6087

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citigroup's LPCN Position: Q4 2025 in Review

Citigroup sold out of Lipocine (LPCN) in Q4 2025, closing a stake of 3 shares — an estimated $9 sold.

Citigroup first reported a position in LPCN in Q4 2014 and held it in 12 quarters. The position peaked at $61K in Q4 2016. 26 funds tracked by Wall St. Rank hold LPCN as of Q4 2025.

  • Citigroup reported no remaining Lipocine position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 3 Lipocine shares in Q4 2025, an estimated $9.
  • Citigroup first reported a position in Lipocine in Q4 2014 and held it in 12 quarters.
  • Citigroup's Lipocine position peaked at $61K in Q4 2016.
  • 26 funds tracked by Wall St. Rank held Lipocine as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.